Phenylketonuria and Hereditary Tyrosinemia: Comparison
View Latest Version
Please note this is a comparison between Version 3 by Camila Xu and Version 2 by Camila Xu.

A delicate intracellular balance among protein synthesis, folding, and degradation is essential to maintaining protein homeostasis or proteostasis, and it is challenged by genetic and environmental factors. Molecular chaperones and the ubiquitin proteasome system (UPS) play a vital role in proteostasis for normal cellular function. As part of protein quality control, molecular chaperones recognize misfolded proteins and assist in their refolding. Proteins that are beyond repair or refolding undergo degradation, which is largely mediated by the UPS. The importance of protein quality control is becoming ever clearer, but it can also be a disease-causing mechanism. Diseases such as phenylketonuria (PKU) and hereditary tyrosinemia-I (HT1) are caused due to mutations in PAH and FAH gene, resulting in reduced protein stability, misfolding, accelerated degradation, and deficiency in functional proteins. Misfolded or partially unfolded proteins do not necessarily lose their functional activity completely. Thus, partially functional proteins can be rescued from degradation by molecular chaperones and deubiquitinating enzymes (DUBs). Deubiquitination is an important mechanism of the UPS that can reverse the degradation of a substrate protein by covalently removing its attached ubiquitin molecule. In this review, we discuss the importance of molecular chaperones and DUBs in reducing the severity of PKU and HT1 by stabilizing and rescuing mutant proteins.

  • deubiquitination
  • inhibitors
  • protein quality control
  • proteolysis
  • protein stabilization
Please wait, diff process is still running!

References

  1. Weiss, A.K.H.; Loeffler, J.R.; Liedl, K.R.; Gstach, H.; Jansen-Dürr, P. The fumarylacetoacetate hydrolase (FAH) superfamily of enzymes: Multifunctional enzymes from microbes to mitochondria. Biochem. Soc. Trans. 2018, 46, 295–309. [Google Scholar] [CrossRef]
  2. Flydal, M.I.; Martinez, A. Phenylalanine hydroxylase: Function, structure, and regulation. IUBMB Life 2013, 65, 341–349. [Google Scholar] [CrossRef]
  3. Williams, R.A.; Mamotte, C.D.; Burnett, J.R. Phenylketonuria: An inborn error of phenylalanine metabolism. Clin. Biochem. Rev. 2008, 29, 31–41. [Google Scholar] [PubMed]
  4. Arturo, E.C.; Gupta, K.; Héroux, A.; Stith, L.; Cross, P.J.; Parker, E.J.; Loll, P.J.; Jaffe, E.K. First structure of full-length mammalian phenylalanine hydroxylase reveals the architecture of an autoinhibited tetramer. Proc. Natl. Acad. Sci. USA 2016, 113, 2394–2399. [Google Scholar] [CrossRef]
  5. Arturo, E.C.; Gupta, K.; Hansen, M.R.; Borne, E.; Jaffe, E.K. Biophysical characterization of full-length human phenylalanine hydroxylase provides a deeper understanding of its quaternary structure equilibrium. J. Biol. Chem. 2019, 294, 10131–10145. [Google Scholar] [CrossRef] [PubMed]
  6. Timm, D.E.; Mueller, H.A.; Bhanumoorthy, P.; Harp, J.M.; Bunick, G.J. Crystal structure and mechanism of a carbon-carbon bond hydrolase. Structure 1999, 7, 1023–1033. [Google Scholar] [CrossRef]
  7. Macias, I.; Laín, A.; Bernardo-Seisdedos, G.; Gil, D.; Gonzalez, E.; Falcon-Perez, J.M.; Millet, O. Hereditary tyrosinemia type I-associated mutations in fumarylacetoacetate hydrolase reduce the enzyme stability and increase its aggregation rate. J. Biol. Chem. 2019, 294, 13051–13060. [Google Scholar] [CrossRef]
  8. Angileri, F.; Bergeron, A.; Morrow, G.; Lettre, F.; Gray, G.; Hutchin, T.; Ball, S.; Tanguay, R.M. Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1. JIMD Rep. 2015, 19, 43–58. [Google Scholar] [CrossRef]
  9. Scriver, C.R. The PAH gene, phenylketonuria, and a paradigm shift. Hum. Mutat. 2007, 28, 831–845. [Google Scholar] [CrossRef]
  10. Medes, G. A new error of tyrosine metabolism: Tyrosinosis. The intermediary metabolism of tyrosine and phenylalanine. Biochem. J. 1932, 26, 917–940. [Google Scholar] [CrossRef]
  11. Lindblad, B.; Lindstedt, S.; Steen, G. On the enzymic defects in hereditary tyrosinemia. Proc. Natl. Acad. Sci. USA 1977, 74, 4641–4645. [Google Scholar] [CrossRef]
  12. Fällström, S.-P.; Lindblad, B.; Lindstedt, S.; Steen, G. Hereditary tyrosinemia-fumarylacetoacetase deficiency. Pediatric Res. 1979, 13, 78. [Google Scholar] [CrossRef]
  13. Berger, R.; Smit, G.P.; Stoker-de Vries, S.A.; Duran, M.; Ketting, D.; Wadman, S.K. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia. Clin. Chim. Acta 1981, 114, 37–44. [Google Scholar] [CrossRef]
  14. Kvittingen, E.; Jellum, E.; Stokke, O. Assay of fumarylacetoacetate fumarylhydrolase in human liver—Deficient activity in a case of hereditary tyrosinemia. Clin. Chim. Acta 1981, 115, 311–319. [Google Scholar] [CrossRef]
  15. Cassiman, D.; Zeevaert, R.; Holme, E.; Kvittingen, E.A.; Jaeken, J. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): A case report. Orphanet J. Rare Dis. 2009, 4, 28. [Google Scholar] [CrossRef] [PubMed]
  16. Garbade, S.F.; Shen, N.; Himmelreich, N.; Haas, D.; Trefz, F.K.; Hoffmann, G.F.; Burgard, P.; Blau, N. Allelic phenotype values: A model for genotype-based phenotype prediction in phenylketonuria. Genet. Med. 2019, 21, 580–590. [Google Scholar] [CrossRef]
  17. Richards, D.Y.; Winn, S.R.; Dudley, S.; Nygaard, S.; Mighell, T.L.; Grompe, M.; Harding, C.O. AAV-Mediated CRISPR/Cas9 Gene Editing in Murine Phenylketonuria. Mol. Ther. Methods Clin. Dev. 2020, 17, 234–245. [Google Scholar] [CrossRef]
  18. van Spronsen, F.J.; van Rijn, M.; Bekhof, J.; Koch, R.; Smit, P.G. Phenylketonuria: Tyrosine supplementation in phenylalanine-restricted diets. Am. J. Clin. Nutr. 2001, 73, 153–157. [Google Scholar] [CrossRef]
  19. Pecimonova, M.; Kluckova, D.; Csicsay, F.; Reblova, K.; Krahulec, J.; Procházkova, D.; Skultety, L.; Kadasi, L.; Soltysova, A. Structural and Functional Impact of Seven Missense Variants of Phenylalanine Hydroxylase. Genes 2019, 10, 459. [Google Scholar] [CrossRef]
  20. Flydal, M.I.; Alcorlo-Pagés, M.; Johannessen, F.G.; Martínez-Caballero, S.; Skjærven, L.; Fernandez-Leiro, R.; Martinez, A.; Hermoso, J.A. Structure of full-length human phenylalanine hydroxylase in complex with tetrahydrobiopterin. Proc. Natl. Acad. Sci. USA 2019, 116, 11229–11234. [Google Scholar] [CrossRef] [PubMed]
  21. Wettstein, S.; Underhaug, J.; Perez, B.; Marsden, B.D.; Yue, W.W.; Martinez, A.; Blau, N. Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria. Eur. J. Hum. Genet. 2015, 23, 302–309. [Google Scholar] [CrossRef] [PubMed]
  22. Jaffe, E.K. New protein structures provide an updated understanding of phenylketonuria. Mol. Genet. Metab. 2017, 121, 289–296. [Google Scholar] [CrossRef] [PubMed]
  23. Patel, D.; Kopec, J.; Fitzpatrick, F.; McCorvie, T.J.; Yue, W.W. Structural basis for ligand-dependent dimerization of phenylalanine hydroxylase regulatory domain. Sci. Rep. 2016, 6, 23748. [Google Scholar] [CrossRef] [PubMed]
  24. Sarkissian, C.N.; Ying, M.; Scherer, T.; Thöny, B.; Martinez, A. The mechanism of BH4 -responsive hyperphenylalaninemia—As it occurs in the ENU1/2 genetic mouse model. Hum. Mutat. 2012, 33, 1464–1473. [Google Scholar] [CrossRef] [PubMed]
  25. Jung-Kc, K.; Himmelreich, N.; Prestegård, K.S.; Shi, T.S.; Scherer, T.; Ying, M.; Jorge-Finnigan, A.; Thöny, B.; Blau, N.; Martinez, A. Phenylalanine hydroxylase variants interact with the co-chaperone DNAJC12. Hum. Mutat. 2019, 40, 483–494. [Google Scholar] [CrossRef] [PubMed]
  26. Eichinger, A.; Danecka, M.K.; Möglich, T.; Borsch, J.; Woidy, M.; Büttner, L.; Muntau, A.C.; Gersting, S.W. Secondary BH4 deficiency links protein homeostasis to regulation of phenylalanine metabolism. Hum. Mol. Genet. 2018, 27, 1732–1742. [Google Scholar] [CrossRef]
  27. Waters, P.J. Degradation of mutant proteins, underlying “loss of function” phenotypes, plays a major role in genetic disease. Curr. Issues Mol. Biol. 2001, 3, 57–65. [Google Scholar]
  28. Wang, J.; Maldonado, M.A. The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol. Immunol. 2006, 3, 255–261. [Google Scholar] [PubMed]
  29. Døskeland, A.P.; Flatmark, T. Conjugation of phenylalanine hydroxylase with polyubiquitin chains catalysed by rat liver enzymes. Biochim. Biophys. Acta 2001, 1547, 379–386. [Google Scholar] [CrossRef]
  30. Blau, N.; Martinez, A.; Hoffmann, G.F.; Thöny, B. DNAJC12 deficiency: A new strategy in the diagnosis of hyperphenylalaninemias. Mol. Genet. Metab. 2018, 123, 1–5. [Google Scholar] [CrossRef] [PubMed]
  31. Scheller, R.; Stein, A.; Nielsen, S.V.; Marin, F.I.; Gerdes, A.M.; Di Marco, M.; Papaleo, E.; Lindorff-Larsen, K.; Hartmann-Petersen, R. Toward mechanistic models for genotype-phenotype correlations in phenylketonuria using protein stability calculations. Hum. Mutat. 2019, 40, 444–457. [Google Scholar] [CrossRef] [PubMed]
  32. Gersting, S.W.; Kemter, K.F.; Staudigl, M.; Messing, D.D.; Danecka, M.K.; Lagler, F.B.; Sommerhoff, C.P.; Roscher, A.A.; Muntau, A.C. Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability. Am. J. Hum. Genet. 2008, 83, 5–17. [Google Scholar] [CrossRef]
  33. Bergeron, A.; D’Astous, M.; Timm, D.E.; Tanguay, R.M. Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1. J. Biol. Chem. 2001, 276, 15225–15231. [Google Scholar] [CrossRef] [PubMed]
  34. Stone, W.L.; Basit, H.; Los, E. Phenylketonuria. In StatPearls [Internet]; StatPearls Publishing: St. Petersburg, FL, USA, 2019. [Google Scholar]
  35. Shi, Z.; Sellers, J.; Moult, J. Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase. Proteins 2012, 80, 61–70. [Google Scholar] [CrossRef]
  36. Sandhu, I.S.; Maksim, N.J.; Amouzougan, E.A.; Gallion, B.W.; Raviele, A.L.; Ooi, A. Sustained NRF2 activation in hereditary leiomyomatosis and renal cell cancer (HLRCC) and in hereditary tyrosinemia type 1 (HT1). Biochem. Soc. Trans. 2015, 43, 650–656. [Google Scholar] [CrossRef] [PubMed]
  37. Regier, D.S.; Greene, C.L. Phenylalanine Hydroxylase Deficiency; Adam, M.P., Ardinger, H.H., Pagon, R.A., Wallace, S.E., Bean, L.J.H., Stephens, K., Amemiya, A., Eds.; GeneReviews®; University of Washington: Seattle, WA, USA, 1993. [Google Scholar]
  38. Underhaug, J.; Aubi, O.; Martinez, A. Phenylalanine hydroxylase misfolding and pharmacological chaperones. Curr. Top. Med. Chem. 2012, 12, 2534–2545. [Google Scholar] [CrossRef]
  39. Muntau, A.C.; du Moulin, M.; Feillet, F. Diagnostic and therapeutic recommendations for the treatment of hyperphenylalaninemia in patients 0–4 years of age. Orphanet J. Rare Dis. 2018, 13, 173. [Google Scholar] [CrossRef]
  40. Sheth, J.J.; Ankleshwaria, C.M.; Pawar, R.; Sheth, F.J. Identification of Novel Mutations in FAH Gene and Prenatal Diagnosis of Tyrosinemia in Indian Family. Case Rep. Genet. 2012, 2012, 428075. [Google Scholar] [CrossRef]
  41. Loeber, J.G. Neonatal screening in Europe; the situation in 2004. J. Inherit. Metab. Dis. 2007, 30, 430–438. [Google Scholar] [CrossRef]
  42. Gundorova, P.; Stepanova, A.A.; Kuznetsova, I.A.; Kutsev, S.I.; Polyakov, A.V. Genotypes of 2579 patients with phenylketonuria reveal a high rate of BH4 non-responders in Russia. PLoS ONE 2019, 14, e0211048. [Google Scholar] [CrossRef]
  43. Zhang, X.; Chen, H.X.; Li, C.; Zhang, G.; Liao, S.Y.; Peng, Z.C.; Lai, X.P.; Wang, L.L. Rapid detection of PAH gene mutations in Chinese people. BMC Med. Genet. 2019, 20, 135. [Google Scholar] [CrossRef] [PubMed]
  44. Biglari, A.; Saffari, F.; Rashvand, Z.; Alizadeh, S.; Najafipour, R.; Sahmani, M. Mutations of the phenylalanine hydroxylase gene in Iranian patients with phenylketonuria. Springerplus 2015, 4, 542. [Google Scholar] [CrossRef] [PubMed]
  45. Dursun, A.; Ozgül, R.K.; Sivri, S.; Tokatlı, A.; Güzel, A.; Mesci, L.; Kılıç, M.; Aliefendioglu, D.; Ozçay, F.; Gündüz, M.; et al. Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease. JIMD Rep. 2011, 1, 17–21. [Google Scholar] [CrossRef] [PubMed]
  46. Yasir Zahoor, M.; Cheema, H.A.; Ijaz, S.; Fayyaz, Z. Genetic Analysis of Tyrosinemia Type 1 and Fructose-1, 6 Bisphosphatase Deficiency Affected Pakistani Cohorts. Fetal Pediatr. Pathol. 2019, 1–11. [Google Scholar] [CrossRef]
  47. Pilla, E.; Schneider, K.; Bertolotti, A. Coping with Protein Quality Control Failure. Annu. Rev. Cell Dev. Biol. 2017, 33, 439–465. [Google Scholar] [CrossRef]
  48. Wolff, S.; Weissman, J.S.; Dillin, A. Differential scales of protein quality control. Cell 2014, 157, 52–64. [Google Scholar] [CrossRef]
  49. Zhou, H.X. Influence of crowded cellular environments on protein folding, binding, and oligomerization: Biological consequences and potentials of atomistic modeling. FEBS Lett. 2013, 587, 1053–1061. [Google Scholar] [CrossRef]
  50. Ashaq, I.; Shajrul, A.; Akbar, M.; Rashid, F. Protein misfolding diseases: In perspective of gain and loss of function. In Proteostasis and Chaperone Surveillance; Springer: Berlin, Germany, 2015; pp. 105–118. [Google Scholar]
  51. Lodish, H.; Berk, A.; Zipursky, S.L.; Matsudaira, P.; Baltimore, D.; Darnell, J. Hierarchical structure of proteins. In Molecular Cell Biology, 4th ed.; WH Freeman: New York, NY, USA, 2000. [Google Scholar]
  52. Alberts, B.; Johnson, A.; Lewis, J.; Raff, M.; Roberts, K.; Walter, P. The shape and structure of proteins. In Molecular Biology of the Cell, 4th ed.; Garland Science: New York, NY, USA, 2002. [Google Scholar]
  53. Hartl, F.U.; Hayer-Hartl, M. Converging concepts of protein folding in vitro and in vivo. Nat. Struct. Mol. Biol. 2009, 16, 574–581. [Google Scholar] [CrossRef]
  54. Chen, B.; Retzlaff, M.; Roos, T.; Frydman, J. Cellular strategies of protein quality control. Cold Spring Harb. Perspect. Biol. 2011, 3, a004374. [Google Scholar] [CrossRef] [PubMed]
  55. Hartl, F.U. Protein Misfolding Diseases. Annu. Rev. Biochem. 2017, 86, 21–26. [Google Scholar] [CrossRef]
  56. Sahni, N.; Yi, S.; Taipale, M.; Fuxman Bass, J.I.; Coulombe-Huntington, J.; Yang, F.; Peng, J.; Weile, J.; Karras, G.I.; Wang, Y.; et al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell 2015, 161, 647–660. [Google Scholar] [CrossRef] [PubMed]
  57. Fredrickson, E.K.; Gardner, R.G. Selective destruction of abnormal proteins by ubiquitin-mediated protein quality control degradation. Semin. Cell Dev. Biol. 2012, 23, 530–537. [Google Scholar] [CrossRef]
  58. Tyedmers, J.; Mogk, A.; Bukau, B. Cellular strategies for controlling protein aggregation. Nat. Rev. Mol. Cell Biol. 2010, 11, 777–788. [Google Scholar] [CrossRef]
  59. Duncan, E.J.; Cheetham, M.E.; Chapple, J.P.; van der Spuy, J. The role of HSP70 and its co-chaperones in protein misfolding, aggregation and disease. Subcell. Biochem. 2015, 78, 243–273. [Google Scholar] [CrossRef]
  60. Finka, A.; Sharma, S.K.; Goloubinoff, P. Multi-layered molecular mechanisms of polypeptide holding, unfolding and disaggregation by HSP70/HSP110 chaperones. Front. Mol. Biosci. 2015, 2, 29. [Google Scholar] [CrossRef] [PubMed]
  61. Jørgensen, M.M.; Jensen, O.N.; Holst, H.U.; Hansen, J.J.; Corydon, T.J.; Bross, P.; Bolund, L.; Gregersen, N. Grp78 is involved in retention of mutant low density lipoprotein receptor protein in the endoplasmic reticulum. J. Biol. Chem. 2000, 275, 33861–33868. [Google Scholar] [CrossRef] [PubMed]
  62. Gámez, A.; Pérez, B.; Ugarte, M.; Desviat, L.R. Expression analysis of phenylketonuria mutations. Effect on folding and stability of the phenylalanine hydroxylase protein. J. Biol. Chem. 2000, 275, 29737–29742. [Google Scholar] [CrossRef]
  63. Bross, P.; Andresen, B.S.; Gregersen, N. Impaired folding and subunit assembly as disease mechanism: The example of medium-chain acyl-CoA dehydrogenase deficiency. Prog. Nucleic Acid Res. Mol. Biol. 1998, 58, 301–337. [Google Scholar] [CrossRef]
  64. Hartl, F.U.; Bracher, A.; Hayer-Hartl, M. Molecular chaperones in protein folding and proteostasis. Nature 2011, 475, 324–332. [Google Scholar] [CrossRef]
  65. Hartl, F.U.; Hayer-Hartl, M. Molecular chaperones in the cytosol: From nascent chain to folded protein. Science 2002, 295, 1852–1858. [Google Scholar] [CrossRef]
  66. Kriegenburg, F.; Jakopec, V.; Poulsen, E.G.; Nielsen, S.V.; Roguev, A.; Krogan, N.; Gordon, C.; Fleig, U.; Hartmann-Petersen, R. A chaperone-assisted degradation pathway targets kinetochore proteins to ensure genome stability. PLoS Genet. 2014, 10, e1004140. [Google Scholar] [CrossRef] [PubMed]
  67. Demand, J.; Alberti, S.; Patterson, C.; Höhfeld, J. Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr. Biol. 2001, 11, 1569–1577. [Google Scholar] [CrossRef]
  68. Ciechanover, A.; Kwon, Y.T. Protein Quality Control by Molecular Chaperones in Neurodegeneration. Front. Neurosci. 2017, 11, 185. [Google Scholar] [CrossRef]
  69. Radons, J. The human HSP70 family of chaperones: Where do we stand? Cell Stress Chaperones 2016, 21, 379–404. [Google Scholar] [CrossRef]
  70. Li, J.; Soroka, J.; Buchner, J. The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones. Biochim. Biophys. Acta 2012, 1823, 624–635. [Google Scholar] [CrossRef] [PubMed]
  71. Karagöz, G.E.; Rüdiger, S.G. Hsp90 interaction with clients. Trends Biochem. Sci. 2015, 40, 117–125. [Google Scholar] [CrossRef]
  72. Taipale, M.; Jarosz, D.F.; Lindquist, S. HSP90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Rev. Mol. Cell. Biol. 2010, 11, 515–528. [Google Scholar] [CrossRef] [PubMed]
  73. Röhl, A.; Rohrberg, J.; Buchner, J. The chaperone Hsp90: Changing partners for demanding clients. Trends Biochem. Sci. 2013, 38, 253–262. [Google Scholar] [CrossRef] [PubMed]
  74. Pearl, L.H.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75, 271–294. [Google Scholar] [CrossRef]
  75. Horwich, A.L.; Fenton, W.A. Chaperonin-assisted protein folding: A chronologue. Q. Rev. Biophys. 2020, 53, e4. [Google Scholar] [CrossRef]
  76. Dun, M.D.; Aitken, R.J.; Nixon, B. The role of molecular chaperones in spermatogenesis and the post-testicular maturation of mammalian spermatozoa. Hum. Reprod. Update 2012, 18, 420–435. [Google Scholar] [CrossRef] [PubMed]
  77. Cyr, D.M.; Ramos, C.H. Specification of Hsp70 function by Type I and Type II Hsp40. Subcell. Biochem. 2015, 78, 91–102. [Google Scholar] [CrossRef]
  78. Yim, W.W.; Mizushima, N. Lysosome biology in autophagy. Cell Discov. 2020, 6, 6. [Google Scholar] [CrossRef] [PubMed]
  79. Sarodaya, N.; Karapurkar, J.; Kim, K.S.; Hong, S.H.; Ramakrishna, S. The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies. Cancers 2020, 12, 1103. [Google Scholar] [CrossRef] [PubMed]
  80. Haq, S.; Ramakrishna, S. Deubiquitylation of deubiquitylases. Open Biol. 2017, 7, 170016. [Google Scholar] [CrossRef] [PubMed]
  81. Zheng, Q.; Huang, T.; Zhang, L.; Zhou, Y.; Luo, H.; Xu, H.; Wang, X. Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases. Front. Aging Neurosci. 2016, 8, 303. [Google Scholar] [CrossRef]
  82. Díaz-Villanueva, J.F.; Díaz-Molina, R.; García-González, V. Protein Folding and Mechanisms of Proteostasis. Int. J. Mol. Sci. 2015, 16, 17193–17230. [Google Scholar] [CrossRef]
  83. Campanella, C.; Pace, A.; Caruso Bavisotto, C.; Marzullo, P.; Marino Gammazza, A.; Buscemi, S.; Palumbo Piccionello, A. Heat Shock Proteins in Alzheimer’s Disease: Role and Targeting. Int. J. Mol. Sci. 2018, 19, 2603. [Google Scholar] [CrossRef]
  84. Das, S.; Ramakrishna, S.; Kim, K.S. Critical Roles of Deubiquitinating Enzymes in the Nervous System and Neurodegenerative Disorders. Mol. Cells 2020, 43, 203–214. [Google Scholar] [CrossRef]
  85. Poondla, N.; Chandrasekaran, A.P.; Kim, K.S.; Ramakrishna, S. Deubiquitinating enzymes as cancer biomarkers: New therapeutic opportunities? BMB Rep. 2019, 52, 181–189. [Google Scholar] [CrossRef]
  86. Nanduri, B.; Suvarnapunya, A.E.; Venkatesan, M.; Edelmann, M.J. Deubiquitinating enzymes as promising drug targets for infectious diseases. Curr. Pharm. Des. 2013, 19, 3234–3247. [Google Scholar] [CrossRef]
  87. Wang, Y.-T.; Chen, G.-C. The role of ubiquitin system in autophagy. In Autophagy in Current Trends in Cellular Physiology and Pathology; In Tech: Rijeka, Croatia, 2016. [Google Scholar]
  88. Kevei, É.; Pokrzywa, W.; Hoppe, T. Repair or destruction-an intimate liaison between ubiquitin ligases and molecular chaperones in proteostasis. FEBS Lett. 2017, 591, 2616–2635. [Google Scholar] [CrossRef] [PubMed]
  89. Srinivasan, V.; Bruelle, C.; Scifo, E.; Pham, D.D.; Soliymani, R.; Lalowski, M.; Lindholm, D. Dynamic Interaction of USP14 with the Chaperone HSC70 Mediates Crosstalk between the Proteasome, ER Signaling, and Autophagy. iScience 2020, 23, 100790. [Google Scholar] [CrossRef] [PubMed]
  90. He, W.T.; Zheng, X.M.; Zhang, Y.H.; Gao, Y.G.; Song, A.X.; van der Goot, F.G.; Hu, H.Y. Cytoplasmic Ubiquitin-Specific Protease 19 (USP19) Modulates Aggregation of Polyglutamine-Expanded Ataxin-3 and Huntingtin through the HSP90 Chaperone. PLoS ONE 2016, 11, e0147515. [Google Scholar] [CrossRef]
  91. Lee, J.G.; Kim, W.; Gygi, S.; Ye, Y. Characterization of the deubiquitinating activity of USP19 and its role in endoplasmic reticulum-associated degradation. J. Biol. Chem. 2014, 289, 3510–3517. [Google Scholar] [CrossRef] [PubMed]
  92. Gallego, D.; Leal, F.; Gámez, A.; Castro, M.; Navarrete, R.; Sanchez-Lijarcio, O.; Vitoria, I.; Bueno-Delgado, M.; Belanger-Quintana, A.; Morais, A.; et al. Pathogenic variants of DNAJC12 and evaluation of the encoded cochaperone as a genetic modifier of hyperphenylalaninemia. Hum. Mutat. 2020, 41, 1329–1338. [Google Scholar] [CrossRef] [PubMed]
  93. Blau, N.; Erlandsen, H. The metabolic and molecular bases of tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. Mol. Genet. Metab. 2004, 82, 101–111. [Google Scholar] [CrossRef] [PubMed]
  94. Pey, A.L.; Stricher, F.; Serrano, L.; Martinez, A. Predicted effects of missense mutations on native-state stability account for phenotypic outcome in phenylketonuria, a paradigm of misfolding diseases. Am. J. Hum. Genet. 2007, 81, 1006–1024. [Google Scholar] [CrossRef]
  95. Yang, S.; Siepka, S.M.; Cox, K.H.; Kumar, V.; de Groot, M.; Chelliah, Y.; Chen, J.; Tu, B.; Takahashi, J.S. Tissue-specific FAH deficiency alters sleep-wake patterns and results in chronic tyrosinemia in mice. Proc. Natl. Acad. Sci. USA 2019, 116, 22229–22236. [Google Scholar] [CrossRef]
  96. Shen, N.; Heintz, C.; Thiel, C.; Okun, J.G.; Hoffmann, G.F.; Blau, N. Co-expression of phenylalanine hydroxylase variants and effects of interallelic complementation on in vitro enzyme activity and genotype-phenotype correlation. Mol. Genet. Metab. 2016, 117, 328–335. [Google Scholar] [CrossRef]
  97. Liang, Y.; Huang, M.Z.; Cheng, C.Y.; Chao, H.K.; Fwu, V.T.; Chiang, S.H.; Hsiao, K.J.; Niu, D.M.; Su, T.S. The mutation spectrum of the phenylalanine hydroxylase (PAH) gene and associated haplotypes reveal ethnic heterogeneity in the Taiwanese population. J. Hum. Genet. 2014, 59, 145–152. [Google Scholar] [CrossRef] [PubMed]
  98. Cerreto, M.; Cavaliere, P.; Carluccio, C.; Amato, F.; Zagari, A.; Daniele, A.; Salvatore, F. Natural phenylalanine hydroxylase variants that confer a mild phenotype affect the enzyme’s conformational stability and oligomerization equilibrium. Biochim. Biophys. Acta 2011, 1812, 1435–1445. [Google Scholar] [CrossRef] [PubMed]
  99. Pey, A.L.; Pérez, B.; Desviat, L.R.; Martínez, M.A.; Aguado, C.; Erlandsen, H.; Gámez, A.; Stevens, R.C.; Thórólfsson, M.; Ugarte, M.; et al. Mechanisms underlying responsiveness to tetrahydrobiopterin in mild phenylketonuria mutations. Hum. Mutat. 2004, 24, 388–399. [Google Scholar] [CrossRef] [PubMed]
  100. Barral, J.M.; Broadley, S.A.; Schaffar, G.; Hartl, F.U. Roles of molecular chaperones in protein misfolding diseases. Semin. Cell Dev. Biol. 2004, 15, 17–29. [Google Scholar] [CrossRef]
  101. Anikster, Y.; Haack, T.B.; Vilboux, T.; Pode-Shakked, B.; Thöny, B.; Shen, N.; Guarani, V.; Meissner, T.; Mayatepek, E.; Trefz, F.K.; et al. Biallelic Mutations in DNAJC12 Cause Hyperphenylalaninemia, Dystonia, and Intellectual Disability. Am. J. Hum. Genet. 2017, 100, 257–266. [Google Scholar] [CrossRef]
  102. Valenzuela, V.; Jackson, K.L.; Sardi, S.P.; Hetz, C. Gene Therapy Strategies to Restore ER Proteostasis in Disease. Mol. Ther. 2018, 26, 1404–1413. [Google Scholar] [CrossRef]
  103. Ebrahimi-Fakhari, D.; Wahlster, L.; McLean, P.J. Molecular chaperones in Parkinson’s disease—Present and future. J. Parkinsons Dis. 2011, 1, 299–320. [Google Scholar] [CrossRef]
  104. Aktuglu-Zeybek, A.C.; Zubarioglu, T. Nitisinone: A review. Orphan Drugs Res. Rev. 2017, 7, 25–35. [Google Scholar] [CrossRef]
  105. Angileri, F.; Morrow, G.; Roy, V.; Orejuela, D.; Tanguay, R.M. Heat shock response associated with hepatocarcinogenesis in a murine model of hereditary tyrosinemia type I. Cancers 2014, 6, 998–1019. [Google Scholar] [CrossRef] [PubMed]
  106. Hanpude, P.; Bhattacharya, S.; Dey, A.K.; Maiti, T.K. Deubiquitinating enzymes in cellular signaling and disease regulation. IUBMB Life 2015, 67, 544–555. [Google Scholar] [CrossRef] [PubMed]
  107. Lee, B.H.; Lee, M.J.; Park, S.; Oh, D.C.; Elsasser, S.; Chen, P.C.; Gartner, C.; Dimova, N.; Hanna, J.; Gygi, S.P.; et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 2010, 467, 179–184. [Google Scholar] [CrossRef] [PubMed]
  108. Seneci, P. Targeting Proteasomal Degradation of Soluble, Misfolded Proteins: Ubi Major. In Chemical Modulators of Protein Misfolding and Neurodegenerative Disease; Academic Press: Milan, Italy, 2015; pp. 73–94. [Google Scholar] [CrossRef]
  109. Al Hafid, N.; Christodoulou, J. Phenylketonuria: A review of current and future treatments. Transl. Pediatr. 2015, 4, 304–317. [Google Scholar] [CrossRef] [PubMed]
  110. Strisciuglio, P.; Concolino, D. New Strategies for the Treatment of Phenylketonuria (PKU). Metabolites 2014, 4, 1007–1017. [Google Scholar] [CrossRef]
  111. Malik, S.; NiMhurchadha, S.; Jackson, C.; Eliasson, L.; Weinman, J.; Roche, S.; Walter, J. Treatment Adherence in Type 1 Hereditary Tyrosinaemia (HT1): A Mixed-Method Investigation into the Beliefs, Attitudes and Behaviour of Adolescent Patients, Their Families and Their Health-Care Team. JIMD Rep. 2015, 18, 13–22. [Google Scholar] [CrossRef] [PubMed]
  112. Chinsky, J.M.; Singh, R.; Ficicioglu, C.; van Karnebeek, C.D.M.; Grompe, M.; Mitchell, G.; Waisbren, S.E.; Gucsavas-Calikoglu, M.; Wasserstein, M.P.; Coakley, K.; et al. Diagnosis and treatment of tyrosinemia type I: A US and Canadian consensus group review and recommendations. Genet. Med. 2017, 19. [Google Scholar] [CrossRef]
  113. Yin, H.; Xue, W.; Chen, S.; Bogorad, R.L.; Benedetti, E.; Grompe, M.; Koteliansky, V.; Sharp, P.A.; Jacks, T.; Anderson, D.G. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 2014, 32, 551–553. [Google Scholar] [CrossRef]
  114. VanLith, C.; Guthman, R.; Nicolas, C.T.; Allen, K.; Du, Z.; Joo, D.J.; Nyberg, S.L.; Lillegard, J.B.; Hickey, R.D. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1. Hum. Gene Ther. 2018, 29, 1315–1326. [Google Scholar] [CrossRef]
  115. Sarkissian, C.N.; Gámez, A. Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now? Mol. Genet. Metab. 2005, 86 (Suppl. 1), S22–S26. [Google Scholar] [CrossRef]
  116. Thomas, J.; Levy, H.; Amato, S.; Vockley, J.; Zori, R.; Dimmock, D.; Harding, C.O.; Bilder, D.A.; Weng, H.H.; Olbertz, J.; et al. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Mol. Genet. Metab. 2018, 124, 27–38. [Google Scholar] [CrossRef]
  117. Sarkissian, C.N.; Gámez, A.; Wang, L.; Charbonneau, M.; Fitzpatrick, P.; Lemontt, J.F.; Zhao, B.; Vellard, M.; Bell, S.M.; Henschell, C.; et al. Preclinical evaluation of multiple species of PEGylated recombinant phenylalanine ammonia lyase for the treatment of phenylketonuria. Proc. Natl. Acad. Sci. USA 2008, 105, 20894–20899. [Google Scholar] [CrossRef]
  118. Alexander, I.E.; Cunningham, S.C.; Logan, G.J.; Christodoulou, J. Potential of AAV vectors in the treatment of metabolic disease. Gene Ther. 2008, 15, 831–839. [Google Scholar] [CrossRef] [PubMed]
  119. Rebuffat, A.; Harding, C.O.; Ding, Z.; Thöny, B. Comparison of adeno-associated virus pseudotype 1, 2, and 8 vectors administered by intramuscular injection in the treatment of murine phenylketonuria. Hum. Gene Ther. 2010, 21, 463–477. [Google Scholar] [CrossRef] [PubMed]
  120. Pan, Y.; Shen, N.; Jung-Klawitter, S.; Betzen, C.; Hoffmann, G.F.; Hoheisel, J.D.; Blau, N. CRISPR RNA-guided FokI nucleases repair a PAH variant in a phenylketonuria model. Sci. Rep. 2016, 6, 35794. [Google Scholar] [CrossRef]
  121. Lachmann, R. Sapropterin hydrochloride: Enzyme enhancement therapy for phenylketonuria. Ther. Adv. Endocrinol. Metab. 2011, 2, 127–133. [Google Scholar] [CrossRef] [PubMed]
  122. Charbonneau, M.R.; Isabella, V.M.; Li, N.; Kurtz, C.B. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat. Commun. 2020, 11, 1–11. [Google Scholar]
  123. Alteri, C.J. Can the Microbiome Deliver? A Proof-of-Concept Engineered E. coli PKU Therapeutic. Cell Host Microbe 2019, 25, 473–474. [Google Scholar] [CrossRef]
  124. Kochhar, J.S.; Chan, S.Y.; Ong, P.S.; Kang, L. Clinical therapeutics for phenylketonuria. Drug Deliv. Transl. Res. 2012, 2, 223–237. [Google Scholar] [CrossRef]
  125. Patrawala, M.; Kuruvilla, M.; Li, H. Successful desensitization of Pegvaliase (Palynziq®) in a patient with phenylketonuria. Mol. Genet. Metab. Rep. 2020, 23, 100575. [Google Scholar] [CrossRef]
  126. Markham, A. Pegvaliase: First Global Approval. BioDrugs 2018, 32, 391–395. [Google Scholar] [CrossRef]
  127. Longo, N.; Arnold, G.L.; Pridjian, G.; Enns, G.M.; Ficicioglu, C.; Parker, S.; Cohen-Pfeffer, J.L. Long-term safety and efficacy of sapropterin: The PKUDOS registry experience. Mol. Genet. Metab. 2015, 114, 557–563. [Google Scholar] [CrossRef]
  128. Rohr, F.; Kritzer, A.; Harding, C.O.; Viau, K.; Levy, H.L. Discontinuation of Pegvaliase therapy during maternal PKU pregnancy and postnatal breastfeeding: A case report. Mol. Genet. Metab. Rep. 2020, 22, 100555. [Google Scholar] [CrossRef] [PubMed]
  129. Das, A.M. Clinical utility of nitisinone for the treatment of hereditary tyrosinemia type-1 (HT-1). Appl. Clin. Genet. 2017, 10, 43–48. [Google Scholar] [CrossRef]
  130. Muntau, A.C.; Leandro, J.; Staudigl, M.; Mayer, F.; Gersting, S.W. Innovative strategies to treat protein misfolding in inborn errors of metabolism: Pharmacological chaperones and proteostasis regulators. J. Inherit. Metab. Dis. 2014, 37, 505–523. [Google Scholar] [CrossRef] [PubMed]
  131. Lichter-Konecki, U.; Vockley, J. Phenylketonuria: Current Treatments and Future Developments. Drugs 2019, 79, 495–500. [Google Scholar] [CrossRef]
  132. Ernst, R.; Claessen, J.H.; Mueller, B.; Sanyal, S.; Spooner, E.; van der Veen, A.G.; Kirak, O.; Schlieker, C.D.; Weihofen, W.A.; Ploegh, H.L. Enzymatic blockade of the ubiquitin-proteasome pathway. PLoS Biol. 2011, 8, e1000605. [Google Scholar] [CrossRef]
  133. Wang, Y.; Jiang, X.; Feng, F.; Liu, W.; Sun, H. Degradation of proteins by PROTACs and other strategies. Acta Pharm. Sin. B 2020, 10, 207–238. [Google Scholar] [CrossRef]
  134. Smith, B.E.; Wang, S.L.; Jaime-Figueroa, S.; Harbin, A.; Wang, J.; Hamman, B.D.; Crews, C.M. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat. Commun. 2019, 10, 131. [Google Scholar] [CrossRef] [PubMed]
  135. Nguyen, T.; Ho, M.; Kim, K.; Yun, S.I.; Mizar, P.; Easton, J.W.; Lee, S.S.; Kim, K.K. Suppression of the Ubiquitin Pathway by Small Molecule Binding to Ubiquitin Enhances Doxorubicin Sensitivity of the Cancer Cells. Molecules 2019, 24, 1073. [Google Scholar] [CrossRef] [PubMed]
  136. Landré, V.; Rotblat, B.; Melino, S.; Bernassola, F.; Melino, G. Screening for E3-ubiquitin ligase inhibitors: Challenges and opportunities. Oncotarget 2014, 5, 7988–8013. [Google Scholar] [CrossRef]
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback